PURPOSE We investigated single-nucleotide polymorphisms of the cytidine deaminase gene (CDA), which encodes an enzyme that metabolizes gemcitabine, to clarify the relationship between the single-nucleotide polymorphism 208G>A and the pharmacokinetics and toxicity of gemcitabine in cancer patients treated with gemcitabine plus cisplatin. EXPERIMENTAL DESIGN Six Japanese cancer patients treated...

The research study was designed to compare the safety and efficacy of the regimen of 5-flurouracil with cisplatin of investigational arm with the reference regimen of gemcitabine with cisplatin for the treatment of gallbladder cancer. A total of 60 patients were enrolled in the study. Out of 30 patients enrolled in arm-A (Gemcitabine with Cisplatin) and 30 patients enrolled in arm-B (5-Fluroura...

The present study deals with the synthesis andfunctionalization of mesoporous silica nanoparticles as drug delivery platforms. SBA-15 nanorods with high surface area (1010 m2g-1) were functionalized by post grafting method using 3-mercaptopropyl trimethoxysilane (MPTS). The parent and thiol-functionalized SBA-15 nanorods were used as nanocarriers for an anticancer drug (gemcitabine). The charac...

This study aimed to modify the biological response of cells to ionizing radiation by combination therapy using radio-sensitizer agent and anticancer drug. Super paramagnetic iron oxide nanoparticles (SPIONs) were prepared and used with gemcitabine (Gem). These two agents were encapsulated simultaneously intopoly (D, L-lactic-co-glycolic acid) (PLGA) to form multifunctional drug delivery system....

Pancreatic ductal adenocarcinoma (PDAC) is a devastating diseasewith poor outcomeswith current therapies. Gemcitabine is the primary adjuvant drug used clinically, but its effectiveness is limited. In this study, our objective was to use a rationale-driven approach to identify novel biomarkers for outcome in patients with earlystage resected PDAC treated with adjuvant gemcitabine. Using a synth...

Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours including non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma. Gemcitabine is an analogue of pyrimidine cytosine and functions as an anti-metabolite. Structurally, however, gemcitabine has similarities to 5-aza-2-deoxycytidine (decitabine...

Cyclopentenyl cytosine (CPEC), targetting the de novo biosynthesis of cytidine triphosphate (CTP), increases the cytotoxicity of gemcitabine (2',2'-difluoro-2'-deoxycytidine, dFdC) alone and in combination with irradiation in several human tumour cells in vitro. We investigated whether CPEC enhances the therapeutic ratio of gemcitabine and irradiation in human pancreatic BxPC-3 xenografts and i...

PURPOSE Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs. The aims of this study were to assess the efficacy of the combination of src inhibition and gemcitabine in gemcitabine-resistant breast cancer cells. METHODS AND RESULTS By using colony formation, sphere for...

High-mobility group box 1 (HMGB1) has been found to mediate autophagy during chemotherapy in several cancers. However, whether HMGB1plays a role in autophagy and chemoresistance in bladder cancer is elusive. In this report, HMGB1 expression was found to be increased in 30 primary bladder cancer tissue specimens compared to their matched adjacent non-tumor tissues. While gemcitabine induced apop...

There is an enormous gap between the antiproliferative and in vivo antitumor efficacy of gemcitabine in cell line-based models and its clinical efficacy. This may be due to insensitiveness of the precursor, cancer stem cell (CSC) compartment to cytotoxic agents. The hedgehog pathway is associated with CSC signaling and control. We used a direct xenograft model of pancreatic cancer and a two-sta...